J&J Dodges Claims In 2nd Philly Risperdal Trial

Law360, Philadelphia (March 20, 2015, 2:26 PM EDT) -- A Johnson & Johnson unit notched a victory Friday after a Philadelphia jury cleared the company of liability in a case alleging that it had failed to warn the doctors of a boy who took the antipsychotic drug Risperdal about the risks of female breast growth.

The verdict came after a monthlong trial in the Philadelphia County Court of Common Pleas, in which the jury heard evidence that Janssen Pharmaceuticals Inc. had worked for years to obscure evidence that the drug was linked to growth of...
To view the full article, register now.